VCT220
VICTOR-HTN
Vincentage Pharma Co · Phase 2 · Active, not recruiting · Enrollment 160
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| VCT220 80mg | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
| VCT220 160mg (1) | n/r | n/r | n/r | n/r |
| VCT220 160mg (2) | n/r | n/r | n/r | n/r |
Not shown
- VCT220 80mg: endpoint not reported
- Placebo: endpoint not reported
- VCT220 160mg (1): endpoint not reported
- VCT220 160mg (2): endpoint not reported